Sun Pharma Advanced Research Company Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 to the National Stock Exchange of India Ltd and BSE Limited. The filing, made pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, details the company's adherence to the National Guidelines on Responsible Business Conduct (NGRBC). The report highlights the company's focus on integrating environmental, social, and governance (ESG) principles into its growth strategy as a clinical-stage biopharmaceutical organization.

General Disclosures and Operations

The company reported a total workforce of 466 employees for FY 2025-26, comprising 369 male and 97 female staff. The permanent employee count stood at 279, while other than permanent employees numbered 187. The board of directors includes six members, with two women representing 33% of the board. Key management personnel consists of three individuals, with one woman. The company operates three R&D facilities nationally and one office internationally, serving markets in three states and two countries.

Financial and Capital Metrics

Sun Pharma Advanced Research Company Ltd reported a paid-up capital of ₹32,45,21,588. The company’s turnover for the year was ₹1,87,917 lakh, with a net worth of ₹1,33,359 lakh. The report notes that the company incurred losses during the three immediately preceding financial years; consequently, it was not required to spend on Corporate Social Responsibility (CSR) activities during FY 2025-26.

Environmental Performance

The company disclosed its energy consumption, reporting total energy consumption from non-renewable sources at 18,772 GJ for FY 2025-26, a decrease from 20,600 GJ in the previous year. Water withdrawn totaled 28,891 KL, down from 30,011 KL in FY 2024-25. The company achieved Zero Liquid Discharge by reusing treated water for gardening. Greenhouse gas emissions included 27 metric tonnes of CO2 equivalent for Scope 1 and 3,108 metric tonnes for Scope 2. Total waste generated was 43 metric tonnes, of which 34 metric tonnes were recycled.

Governance and Stakeholder Engagement

The company identified material responsible business conduct issues, including data integrity and security, disruptive climate change events, and talent retention. It maintains grievance redressal mechanisms for shareholders and employees, recording one shareholder complaint in FY 2025-26 which was resolved. The board and key management personnel received 100% coverage in training and awareness programs covering all nine NGRBC principles. The company confirmed compliance with applicable environmental laws and regulations.

Subsidiary Information

As of March 31, 2026, the company’s subsidiaries include SPARCLIFE Inc. and Genokine Biotech Limited, which was incorporated as a wholly owned subsidiary on July 4, 2025. Both subsidiaries participate in the company's Business Responsibility initiatives.

Sun Pharma Advanced Research Company Limited reported a consolidated net profit of ₹1,55,320.43 lakh for the financial year ended March 31, 2026, compared to a net loss of ₹34,250.94 lakh in the previous year. The turnaround was primarily driven by the recognition of income from a Priority Review Voucher (PRV) granted by the USFDA, which was subsequently sold for USD 195 million.

The company’s total income for the year stood at ₹1,88,999.95 lakh, a significant increase from ₹7,355.71 lakh in the previous year. This rise was largely due to the recognition of ₹1,84,002 lakh in respect of the PRV granted on February 03, 2026, for the drug Sezaby®. The PRV, accounted for as a non-monetary government grant under Ind AS 20, was sold on April 30, 2026.

Financial Performance

The consolidated financial results for the year ended March 31, 2026, show a marked improvement in the company’s bottom line. Total revenue from operations was ₹1,87,916.83 lakh, up from ₹7,176.60 lakh in the previous year. The profit before tax for the year was ₹1,55,300.99 lakh, compared to a loss before tax of ₹34,278.12 lakh in the previous year.

The board has not recommended any dividend for the financial year under review.

Corporate Developments

During the year, the company’s board approved a preferential issue of up to 3,85,10,000 warrants to Shanghvi Finance Private Limited, a promoter group entity. The warrants were allotted on May 19, 2026, at an issue price of ₹155.80 per warrant, aggregating to ₹5,99,98,58,000. The company received 25% of the issue price, amounting to ₹1,49,99,64,500, at the time of allotment.

The board also approved the SPARC Employees Stock Option Scheme 2026, though no stock options were granted during the year.

Strategic Focus

The company stated that its strategy is anchored on a differentiated, innovation-led approach. It continues to focus its research and development efforts on oncology and immunology, leveraging advanced modalities such as Antibody Drug Conjugates (ADCs) and CAR-T therapies. The company is also advancing its pipeline in dermatology and autoimmune disorders.